



UNIVERSITÀ DI PARMA

ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation

This is the peer reviewed version of the following article:

Original

Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation / Belotti, Silvia; Rossi, Alessandra; Colombo, Paolo; Bettini, Ruggero; Rekkas, Dimitrios; Politis, Stavros; Colombo, Gaia; Balducci, Anna Giulia; Buttini, Francesca. - In: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. - ISSN 0939-6411. - 93:(2015), pp. 165-172. [10.1016/j.ejpb.2015.03.023]

Availability:

This version is available at: 11381/2787891 since: 2017-05-23T13:29:44Z

Publisher:

Elsevier

Published

DOI:10.1016/j.ejpb.2015.03.023

Terms of use:

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

note finali coverpage

(Article begins on next page)

Graphical Abstract



Amikacin dry powders for inhalation

Central Composite Design



Effect of ethanol on the formation of microparticles

Peclet number and drug solubility



1 *Spray-dried amikacin sulphate powder for inhalation in*
2 *cystic fibrosis patients: the role of ethanol in particle*
3 *formation.*

4 Silvia Belotti^a, Alessandra Rossi^a, Paolo Colombo^a, Ruggero Bettini^a, Dimitrios Rekkas^b,
5 Stavros Politis^b, Gaia Colombo^c, Anna Giulia Balducci^d, Francesca Buttini^a

6

7 a Department of Pharmacy, University of Parma, Viale delle Scienze 27/A, Parma 43124,
8 Italy

9 b School of Pharmacy, University of Athens, Panepistimiopolis Zografou, Athens 15771,
10 Greece

11 c Department of Life Sciences and Biotechnology, University of Ferrara, Via Fossato di
12 Mortara 17/19, Ferrara 44121, Italy

13 d Interdepartmental Center, Biopharmanet-TEC, University of Parma, Viale delle Scienze
14 27/A, Parma 43124, Italy

15

16 **Corresponding Author**

17 Dr. Francesca Buttini,

18 Department of Pharmacy

19 University of Parma,

20 Viale delle Scienze 27/a, 43124 Parma, IT

21 Tel. +39 0521 906008

22 Fax. +39 0521 905006

23 E-mail: francesca.buttini@unipr.it

24

25

26 **KEYWORDS**

27 *amikacin sulphate; dry powder inhaler; Peclet number; microparticles; cystic fibrosis*

28

29 Abbreviation section

30 CCD Central Composite Design

31 CF Cystic Fibrosis

32 CQAs Critical Quality Attributes

33 CPPs Critical Process Parameters

34 DoE Design of Experiments

35 ED Emitted Dose

36 FPD Fine Particle Dose

37

38 Chemical compound studied in this article:

39 Amikacin sulphate (PubChem CID: 45357036)

40

41 Abstract

42 A Central Composite Design (CCD) was applied in order to identify positive combinations of
43 the production parameters of amikacin sulphate spray-dried powders for inhalation, with the
44 intent to expand the experimental space defined in a previous half-fractional factorial design.
45 Three factors, namely drying temperature, feed rate and ethanol proportion, have been
46 selected out of the initial five. In addition, the levels of these factors were increased from two
47 to three and their effect on amikacin respirability was evaluated. In particular, focus was
48 given on the role of ethanol presence on the formation of the microparticles for inhalation.
49 The overall outcome of the CCD was that amikacin respirability was not substantially
50 improved, as the optimum region coincided with areas already explored with the fractional
51 factorial design. However, expanding the design space towards smaller ethanol levels,
52 including its complete absence, revealed the crucial role of this solvent on the morphology of
53 the produced particles. Peclet number and drug solubility in the spraying solution helped to
54 understand the formation mechanism of these amikacin sulphate spray-dried particles.

55

56 1. Introduction

57 Lung infections in Cystic Fibrosis (CF) patients caused by *Pseudomonas aeruginosa* are
58 efficiently managed with antibacterial drugs. These treatments require high doses of
59 antibiotics. However, using the pulmonary route, the inhaled drug is directly deposited on the
60 site of infection providing higher local concentrations with lower doses compared to systemic
61 administration. Dry powder inhalers are able to deliver high payloads of drug in a shorter
62 time, offering a convenient alternative to solutions for nebulization [1]. However, high doses
63 of powders can raise adverse effects during the administration, such as cough and choking.
64 Consequently, there are two approved administration strategies for delivering high doses of
65 powdered drugs to the lung of the patients [2]. The first used a single pre-metered capsule
66 reservoir containing the whole dose to be extracted by successive inhalation acts, such as with
67 the Colobreathe product [3]. The second strategy consisted in splitting the dose in multiple
68 capsule reservoirs. In Tobi Podhaler, the dry powder of tobramycin formulation (112 mg
69 dispersed in approximately 200 mg of powder) is administered by the consecutive inhalation
70 of four capsules content. An evolution of these delivery systems is the use of new disposable
71 devices, capable to gradually release the dose loaded in the device reservoir in alternative to
72 hard capsules [4,5].

73 The performance of a dry powder inhaler is governed by formulation characteristics. Particle
74 engineering strategies have been adopted to optimize size, morphology and structure of
75 microparticles, in order to maximize the respirable fraction of the drug, without
76 compromising the powder flow properties [6,7]. Since the antibiotics are administered at high
77 doses (up to 100-150 mg), formulation techniques should avoid the use of carrier excipients,
78 to limit the mass of the powder to be inhaled [8].

79 Spray drying is a suitable technology towards this direction, as it is capable of providing
80 respirable microparticles for lung administration with acceptable flow properties [9]. The

81 method has been used for the preparation of antibiotic [10-12], anti-inflammatory compounds
82 [13,14] and insulin dry powder [15,16]. The shape and density of the spray-dried particles can
83 be modified by controlling the parameters affecting the evaporation process of the sprayed
84 droplets [17 - 19].

85 In a previous study [20], a half-fractional factorial experimental design was applied as a
86 statistical tool for the construction of amikacin sulphate spray-dried pulmonary powders. The
87 mathematical relationships between six Critical Quality Attributes (CQAs) of the finished
88 product and five Critical Process Parameters (CPPs) were established. Drying temperature,
89 feed rate, ethanol:water ratio, concentration of amikacin sulphate in spraying solution and
90 presence of PEG-32 stearate, as respirability adjuvant, were investigated. The results obtained
91 showed that the proposed adjuvant did not benefit the quality of the spray-dried powders and
92 the best factor combination led to an amikacin sulphate powder with an Emitted Dose of 85%
93 and a respirable fraction reaching 58% of the loaded dose.

94 In the present study, a Central Composite Design has been applied, aiming to expand the
95 experimental space previously defined in the hypothesis to discover further positive
96 combinations of the manufacturing parameters. Therefore, among the previous CPPs, the
97 three most important were amplified at three levels including unexplored regions assumed
98 favourable for increasing amikacin powder respirability. In detail, ethanol proportion, drying
99 temperature and feed rate were evaluated at three levels, including new settings for the first
100 two factors. Special attention has been given to the role of ethanol as solvent in the sprayed
101 solution, with respect to the effect of its absence/presence on final product structure and
102 inhalation performance.

103 2. Materials and methods

104 2.1 Materials

105 Amikacin sulphate was obtained by ACS DOBFAR S.p.a. (Milan, I). All solvents used were
106 of analytical grade. Water was purified by reverse osmosis (MilliQ, Millipore, Guyancourt,
107 France). Hydroxypropylmethylcellulose (HPMC) capsules (size 3) were received from
108 Capsugel (Colmar, France). RS01 Dry Powder Inhaler device flow rate 60 L/min (gift of
109 Plastiapè S.p.a. (Osnago, LC, I).

110 Amikacin sulphate solubility was measured in purified water, in ethanol 95.6° and water
111 ethanol mixtures, using the amikacin assay method of Ph.Eur. 8.

112

113 2.2 Design of Experiments (DoE)

114 A face centred-CCD with three factors at three levels was employed, and the experimental
115 matrix is presented in Table 1. The design was constructed and analysed using Design-
116 Expert[®] Software, Version 9.0.1 (Stat-Ease, Inc., Minneapolis, USA).

117

118 2.3 Preparation of spray-dried powders

119 2.5 g of amikacin sulphate were dissolved in water at room temperature. Ethanol was added
120 under stirring to obtain the proportions reported in Table 1, while drug concentration was kept
121 2% w/v. The solutions prepared were spray-dried using a Büchi Mini Spray Dryer B-290
122 (Büchi Labortechnik, Flawil, Switzerland) coupled to a B-296 de-humidifier, adopting the
123 process parameters reported in Table 1. Aspirator rate was kept constant at 90%, while
124 atomizing air velocity and nozzle cleaning interval were adjusted at 600 L/h and level 5
125 respectively.

126 The spray-dried powder was quantitatively recovered from the product collection vessel and
127 weighed on an analytical balance (E50S, Gibertini, Italy). The yield was expressed as

128 percentage of the solid dissolved in the sprayed solution. The dry product was then stored at
129 room temperature in a 25 ml cylindrical glass vial, sealed with a rubber stopper and
130 aluminium cap. Part of the product was agglomerated into microparticle clusters by sieving as
131 described in a previous publication [20].

132

133 2.4 Powder and agglomerate characterization

134 The morphology of the spray-dried powders was assessed by Scanning Electron Microscopy
135 (SEM) (Sigma HD, Carl Zeiss, Germany), at extra high tension of 1.00 kV. Microparticle
136 samples were placed on a double-sided adhesive tape pre-mounted on an aluminium stub and
137 analysed after a 30 min depressurization.

138 Particle size distribution of spray-dried powders was measured by laser light scattering
139 (SprayTec, Malvern, UK). Approximately 10 mg of sample were dispersed in 20 ml of
140 cyclohexane containing 0.1% w/v of sorbitan monooleate (Span 80) and sonicated for 5 min.
141 The results were expressed in terms of median volume diameter $D_{(v,90)}$, percentiles $D_{(v,10)}$,
142 $D_{(v,50)}$ and Span.

143 The residual water content (%) of the spray-dried powders was measured by Karl Fischer
144 volumetric titration using TitroMatic Karl Fischer (Crison Instruments, S.A., Barcelona,
145 Spain).

146 The bulk density was determined as the ratio of the sample mass and its unsettled apparent
147 bulk volume. The latter was directly measured in a 25 ml cylindrical glass vial.

148 The true density was measured using a helium pycnometer (APS AccuPyc 1330 Gas
149 Pycnometer, Micromeritics, Norcross, GA, USA).

150 The agglomerates were observed by optical microscopy (magnification 3x), and the diameter
151 of the projected area assumed as spherical, was measured using Image J software (U. S.
152 National Institutes of Health, Bethesda, Maryland, USA).

153 The aerodynamic assessment of the spray-dried powders was carried out using the Fast
154 Screening Impactor (FSI) (Copley Scientific, UK). The FSI divides the aerosol particles
155 emitted from the inhaler into two parts, i.e. the coarse and the fine fractions, the latter
156 corresponding to sizes lower than $5\ \mu\text{m}$ considered as respirable fraction. The Coarse Fraction
157 Collector (CFC) is equipped with an insert that enables the $5\ \mu\text{m}$ cut-off at 60 L/min. The
158 particles not captured in the CFC follow the airstream and deposit in the fine fraction
159 collector (FFC) where they are captured by a filter (A/E glass filter, 76 mm, Pall Corporation,
160 USA).

161 In detail, an accurately weighed amount of powder equal to $10 \pm 0.2\ \text{mg}$, was manually
162 introduced into a size 3 hard HPMC capsule. The capsule was then inserted into the holder
163 chamber of the RS01 device and pierced. The latter was connected to the FSI and flushed by
164 the air stream for 4 s at 60 L/min. The FFC filter was weighed before and after the air
165 actuation, in order to determine the amount of powder deposited, termed as Fine Particle Dose
166 (FPD). Each powder was tested in triplicate before and after the agglomeration process.

167

168 2.5 Determination of evaporation rate of spray-dried solutions

169 The evaporation rates of the spray-dried solutions were measured by thermogravimetric
170 analysis (TGA, Mettler Toledo, Columbus, OH, USA). An accurate amount of solution was
171 introduced in an aluminium-crucible $40\ \mu\text{l}$ pan (Me-26763 without pin, Mettler Toledo). The
172 sample was heated into the apparatus furnace at constant temperature of $85\ ^\circ\text{C}$, corresponding
173 to the outlet temperature of spray drying, while purging nitrogen at a flow rate of 20 ml/min.
174 The weight loss was recorded as a function of time [19].

175

176 3. Results and discussion

177 In all experiments the yields of amikacin spray-dried powders exceeded 80%. The residual
178 water content was lower than that of amikacin sulphate active substance, which was 10.7%
179 (Table 2). The lowest residual water content value (4.92%) was obtained for the combination
180 of the high drying temperature (180 °C), low feed rate (2 ml/min) and absence of ethanol in
181 the feed solution (experiment # 6). In contrast, the maximum water content was measured
182 when the low drying temperature (150 °C) was combined with the high level of feed rate (5
183 ml/min) and ethanol proportion (10%) (experiment # 3).

184 The ANOVA analysis of residual water content (numerical data not shown) and the
185 corresponding contour plot (Figure 1) indicated feed rate (B) and ethanol proportion (C) as
186 the most influential factors. The contour plot illustrates that at the drying temperature of 165
187 °C, the highest residual water values are in the red zone, where high percentages of ethanol
188 and feed solution rates are used. Although the effect of increasing the feed rate on residual
189 water is practically self-explanatory, attributing higher water content of dry particles to the
190 increase of ethanol in feed solution required further consideration. This result could be
191 attributed to the different vapour tension of the two miscible liquids. During the drying
192 process, different compositions between the solution to evaporate and the condensed vapour,
193 richer in ethanol, were obtained. Since the evaporation time of the droplets and the drying
194 temperature were constant, the more volatile ethanol, when present, subtracted part of
195 available heat energy to water evaporation, so leaving more residual water in the solid.

196

197 3.1 Morphological analysis

198 The SEM images of the powders produced at different ethanol concentrations (experiments #
199 13-15) reveal peculiar morphological differences between the microparticles (Figure 2).
200 Almost all particles produced without ethanol (experiment # 14) are shrunk. In contrast, in the

201 powders prepared from ethanol solutions (experiments # 13 and 15), together with shrivelled
202 particles, numerous large spherical particles have been observed, captured as either swollen
203 by an inner pressure or ‘exploded’. This condition was more evident at high level of ethanol
204 in the feed solution The blown up or ruptured particles, compared to the shrivelled (collapsed)
205 ones in the absence of ethanol, indicated that water/ethanol evaporation rate during the drying
206 process was the determinant of particle morphology.

207

208 3.2 Particle size distribution and density of powders and agglomerates

209 All spray-dried powders showed a median diameter, $D_{(v,50)}$, between 2.49 and 4.36 μm ,
210 suitable for pulmonary administration (Table 2). Confirming the size observed in the SEM
211 pictures, the presence of ethanol and the increase of feed rate resulted in particles with larger
212 volume diameter and span.

213 With respect to true density, no significant differences were measured, as values ranged
214 between 1.5 and 1.6 g/cm^3 (data not shown). However, bulk density was strongly affected
215 when ethanol was present in the spraying solution of amikacin sulphate. As shown in Figure
216 3, the powders with the highest bulk density values (experiments # 5 to 8, and 14) were
217 obtained from feed solutions without ethanol. Connecting this result with the SEM picture
218 observation, the ethanol-generated large exploded microparticles are the responsible of the
219 powder volume increase and thus, of the bulk density reduction.

220

221 In general, the spray-dried amikacin sulphate powders poorly flowed, since they appeared as
222 lumps of particles having different sizes when collected from the spray drier cyclone. This
223 behaviour made the powder non homogenous, anticipating negative expectations about the
224 operation of loading the device reservoir for drug product preparation (dry powder inhaler).
225 As a consequence, the powders were agglomerated to form soft pellets, in order to
226 homogenize the lumps and improve their flowability and packing characteristics.

227 Agglomeration made the powders free-flowing and increased the bulk density with few
228 exceptions (see Figure 3).

229 During the agglomeration process it was also observed that the spray-dried powders gave rise
230 to two distinct size groups of soft pellets, one group with a projection diameter smaller than
231 0.5 mm (0.16 to 0.47 mm), (powders # 5 to 8 and 14), and the second group with a diameter
232 larger than 0.5 mm (0.58 to 0.85 mm). Agglomerates obtained from powders prepared with
233 feed solutions without ethanol belonged to the first group, whereas the powders prepared with
234 5 or 10% of ethanol entered the second group (Figure 4).

235
236 Having seen that ethanol in the spray-dried amikacin sulphate solution caused different
237 particle morphologies, it can be reasonably assumed that bulk density, water content and size
238 of agglomerates changed in dependence on the ethanol presence in the feed solution. In
239 summary, the agglomeration process, performed by means of a short process of sieve
240 vibration of the microparticles, produced free flowing powders, which facilitated the reservoir
241 dosing of the inhalers.

242

243 3.3 Aerodynamic performance

244 The aerodynamic performance of the powders before and after agglomeration was tested *in*
245 *vitro* using the Fast Screening Impactor. The values of Emitted Dose (ED) and Fine Particle
246 Dose (FPD) obtained are shown in Table 3. The Emitted Doses of the amikacin sulphate
247 powders and agglomerates studied in this work exceeded 72% in many cases, with few
248 significant differences before and after agglomeration. However, it was noticed that the
249 lowest ED values, for both powders and agglomerates, were found when powders were
250 produced without ethanol in the feed solution. FPD values before and after agglomeration
251 ranged between 3.45 - 5.59 mg and 2.86 - 5.30 mg, respectively. The highest FPD values
252 were obtained for powders produced using a feed solution containing 10% of ethanol, which

253 was also the optimum region identified for this factor in the previous fractional factorial
254 design studying the process.

255

256 The graphs in Figure 5 illustrate the values of ED and FPD before and after agglomeration for
257 each powder produced. The graphs did not allow clearly differentiating groups of powders
258 and agglomerates having similar aerodynamic behaviour in dependence on the CPPs.
259 Nevertheless, statistical analysis confirmed that ethanol proportion in the feed solution was
260 the major parameter influencing the powder aerodynamic behaviour, in consequence of the
261 variations in particle structure determined by the solvent presence or absence. This is depicted
262 in the perturbation plots and tridimensional graphs on ED and FPD obtained from the design
263 analysis (Figures 6 and 7).

264

265 While ED is clearly affected only by ethanol presence, FPD is influenced by all three studied
266 factors. In other words, it is evident that ethanol proportions govern ED values, irrespectively
267 of the other two CPPs. Furthermore, a curvature occurs at high ethanol proportions towards
268 the maximum of 10%. This was the optimum ethanol concentration also identified previously
269 [20], in which its levels ranged between 10 and 20%, thus validating the former fractional
270 factorial design.

271 At the same time, ethanol proportion in the same region promotes FPD, while the contribution
272 of Feed Rate and Drying Temperature for this CQA is also significant.

273 As a result of the above, robust regions for the CPPs were identified for optimizing both
274 CQAs simultaneously. For instance, settings assuring high ED are located at 10% ethanol
275 levels, where FPD also maximizes with appropriate adjustment of the other two CPPs, which
276 in turn do not deteriorate ED, as the latter is practically unaffected from their changes.

277

278 3.4 Mechanism of particle formation

279 The amikacin sulphate particle formation mechanism can be identified by determining the
280 Peclet number (P_e) applied to the evaporation of the sprayed droplets of drug solution. P_e
281 depends on the drying rate (k) of the droplet and the diffusion coefficient (D) of drug in the
282 droplet solution, according to the following equation:

$$283 \quad P_e = \frac{k}{8D} \quad (\text{equation 1})$$

284 where k is the evaporation rate constant in cm^2s^{-1} and D is the diffusion coefficient of
285 dissolved substance in the solution. When $P_e \leq 1$, the diffusion velocity of drug molecules in
286 the droplet is faster or of the same order of magnitude of the drying rate. In this case, if the
287 solute has a high solubility in the solvent, during the evaporation process drug precipitation is
288 delayed, leading to dense particles. When $P_e > 1$, drying rate is faster than diffusion rate of
289 solute molecules which accumulate and precipitate at the droplet surface, leading to empty
290 shell particles [9].

291 In this work, evaporation rates of amikacin sulphate in the different feed solutions have been
292 determined by TGA. Solutions containing amikacin sulphate showed a slower evaporation
293 rate compared to the solvent mixtures. The profiles of mass fraction evaporated versus time
294 were linear and the slope was measured as s^{-1} . Since for P_e calculation the evaporation rate
295 constant is measured in surface over time units (cm^2/s), the slope of the evaporation curves
296 ($1/\text{s}$) was multiplied by the evaporating area exposed in the TGA pan (0.26 cm^2), which
297 remained constant during the analysis. The values obtained are shown in Table 4.

298 The amikacin coefficient of diffusion was calculated at 298 K using the following equation
299 [11]:

$$300 \quad \text{Log } D = -4.113 - 0.4609 \log \text{Mw} \quad (\text{equation 2})$$

301 D value of amikacin sulphate in water was determined as $3.58 \cdot 10^{-6} \text{ cm}^2 \text{ s}^{-1}$. Then, assuming
302 that the temperature of evaporating solution equals the outlet temperature during spray drying

303 (85 ° C, i.e., 358 K) and applying the Stokes-Einstein equation [12], D value at 85 °C was
304 determined. Disregarding the presence of ethanol, D approximated equal to $1.30 \cdot 10^{-5} \text{ cm}^2 \text{ s}^{-1}$.
305 The P_e values obtained in this study were higher than 1.0 (Table 4) and not significantly
306 modified by the ethanol presence. This indicates that molecules did not diffuse to the inner
307 part of the droplet because the evaporation rate was faster than diffusion. Thus, amikacin
308 sulphate particle formation was described as a fast recession of the droplet surface with the
309 precipitation of solute at the surface, resulting in formation of a shell void particle. SEM
310 pictures confirmed this predicted formation of void particles. In the particle pictures, the shell
311 of some broken particles and the differences in size depending on the feed solution
312 composition are clearly visible. In fact, numerous swollen and often exploded amikacin
313 sulphate particles have been obtained from the feed solutions containing ethanol. On the
314 contrary, the particles obtained from the feed solution without ethanol were smaller,
315 shrivelled and evidently empty.

316 The formation of these different particle populations has to be attributed to the different
317 amikacin sulphate solubility. The measured solubility of amikacin sulphate in the solvents and
318 their mixtures used is shown in Table 4. Amikacin sulphate is freely soluble in water but
319 practically insoluble in ethanol. The presence of several large particles in the powders made
320 from ethanol:water solutions was attributed to the fact that amikacin sulphate dissolved in
321 water droplets precipitated at the surface later than in the droplets containing ethanol. This
322 was due to the higher solubility of amikacin sulphate in water than in the mixtures with
323 ethanol. Thus, ethanol, decreasing the amikacin sulphate solubility, anticipated its surface
324 precipitation and promoted the formation of swollen, void, often exploded microparticles due
325 to the vapour tension of the ethanol entrapped inside the particle. Amikacin sulphate particles
326 obtained from the feed solution without ethanol were also void, but remain smaller.

327

328 4. Conclusions

329 Using a Central Composite Design including new combinations of the three selected spray
330 drying process and formulation parameters, no further aerodynamic improvement of powders
331 and agglomerates was observed, compared to the previous half-fractional factorial
332 experimental design.

333 In this study, the role of ethanol in the solution to be sprayed was identified as crucial on the
334 formation of amikacin sulphate microparticles and the properties of corresponding powders.
335 Large microparticles with low aerodynamic diameter, high density powders, agglomeration
336 easiness contributed to enhance the respirability of powders obtained in presence of ethanol in
337 sprayed solution, in particular close to 10%. The solubility of amikacin sulphate in
338 water/ethanol mixtures and the evaporation rate (Peclet number) of the sprayed solutions
339 helped to understand the formation mechanism of the deriving spray-dried particles. The
340 effect of ethanol in the sprayed solution was revealed by the appearance in the obtained
341 powder of swollen from inside, empty, often exploded large amikacin sulphate microparticles.
342 The precipitation of amikacin sulphate in the drying droplet of the lower solvent
343 water/ethanol and pressure of ethanol entrapped into the shell particle have been the
344 determinants of the structure of these highly respirable amikacin sulphate microparticles.
345 Other drugs could benefit of this mechanism provided that the solubility and solution
346 composition activate a microparticle formation similar to amikacin sulphate.

347

348 Acknowledgments

349 The authors would like to thank Lisapharma spa (Erba, CO, Italy), Plastiapa Spa (Osnago,
350 LC, Italy) and Capsugel (Colmar, France) for kindly donating the amikacin raw material,
351 RS01 dry powder inhaler and HPMC capsules, respectively.

352

353 **References**

- 354 [1] G. Pilcer, V. De Bueger, K. Traina, H. Traore, T. Sebti, F. Vanderbist, et al., Carrier-free
355 combination for dry powder inhalation of antibiotics in the treatment of lung infections in
356 cystic fibrosis, *Int J Pharm.* 451 (2013) 112–120. doi:10.1016/j.ijpharm.2013.04.069.
- 357 [2] Balducci A.G., Bettini R., Colombo P., Buttini, F. Chapter XI: Drug delivery strategies for
358 pulmonary administration of antibiotics. In: *Pulmonary Drug Delivery: Advances and
359 Challenges*. Nokhodchi, A., Martin, G.P. (Eds.), Wiley-Blackwell, Chichester, West Sussex,
360 UK (in press).
- 361 [3]
362 [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001225/human_me
364 d_001507.jsp&mid=WC0b01ac058001d124](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001225/human_me
363 d_001507.jsp&mid=WC0b01ac058001d124) (last access on March 03, 2015)
- 364 [4] A.H. de Boer, P. Hagedoorn, E.M. Westerman, P.P.H. Le Brun, H.G.M. Heijerman, H.W.
365 Frijlink, Design and in vitro performance testing of multiple air classifier technology in a new
366 disposable inhaler concept (Twincer) for high powder doses, *Eur J Pharm Sci.* 28 (2006) 171–
367 178. doi:10.1016/j.ejps.2005.11.013.
- 368 [5] P.M. Young, J. Crapper, G. Philips, K. Sharma, H.-K. Chan, D. Traini, Overcoming Dose
369 Limitations Using the Orbital® Multi-Breath Dry Powder Inhaler, *J Aerosol Med Pulm Drug
370 Deliv.* 27 (2014) 138–147. doi:10.1089/jamp.2013.1080.
- 371 [6] G. Pilcer, F. Vanderbist, K. Amighi, Preparation and characterization of spray-dried
372 tobramycin powders containing nanoparticles for pulmonary delivery, *Int J Pharm.* 365 (2009)
373 162–169. doi:10.1016/j.ijpharm.2008.08.014.
- 374 [7] A. Schoubben, P. Blasi, M.L. Marenzoni, L. Barberini, S. Giovagnoli, C. Cirotto, et al.,
375 Capreomycin supergenerics for pulmonary tuberculosis treatment: preparation, in vitro, and in
376 vivo characterization, *Eur J Pharm Biopharm.* 83 (2013) 388–395.
377 doi:10.1016/j.ejpb.2012.11.005.
- 378 [8] S. Claus, C. Weiler, J. Schiewe, W. Friess, How can we bring high drug doses to the lung? *Eur
379 J Pharm Biopharm.* (2013) 1–6. doi:10.1016/j.ejpb.2013.11.005.
- 380 [9] F. Buttini, P. Colombo, A. Rossi, F. Sonvico, G. Colombo, Particles and powders: tools of
381 innovation for non-invasive drug administration, *J Control Release.* 161 (2012) 693–702.
382 doi:10.1016/j.jconrel.2012.02.028.
- 383 [10] D.E. Geller, J. Weers, S. Heuerding, Development of an inhaled dry-powder formulation of
384 tobramycin using PulmoSphere™ technology, *J Aerosol Med Pulm Drug Deliv.* 24 (2011)
385 175–182. doi:10.1089/jamp.2010.0855.

- 386 [11] Buttini F, et al, 2010, A drug powder for inhalation administration and a process thereof.
387 WO2010003465 (A2).
- 388 [12] C. Parlati, P. Colombo, F. Buttini, P.M. Young, H. Adi, A.J. Ammit, et al., Pulmonary spray-
389 dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency,
390 Pharm Res. 26 (2009) 1084–1092. doi:10.1007/s11095-009-9825-2.
- 391 [13] A. Pomázi, F. Buttini, R. Ambrus, P. Colombo, Effect of polymers for aerolisation properties
392 of mannitolbased microcomposites containing meloxicam, European Polymer J 49 (2013)
393 2518-2527. doi:10.1016/j.eurpolymj.2013.03.017.
- 394 [14] F. Buttini, P. Colombo, M.P.E. Wenger, P. Mesquida, C. Marriott, S.A. Jones, Back to basics:
395 the development of a simple, homogenous, two-component dry-powder inhaler formulation
396 for the delivery of budesonide using miscible vinyl polymers, J Pharm Sci. 97 (2008) 1257–
397 1267. doi:10.1002/jps.21126.
- 398 [15] T.S. Cavaiola, S. Edelman, Inhaled insulin: a breath of fresh air? A review of inhaled insulin,
399 Clin Ther. 36 (2014) 1275–1289. doi:10.1016/j.clinthera.2014.06.025.
- 400 [16] A.G. Balducci, S. Cagnani, F. Sonvico, A. Rossi, P. Barata, G. Colombo, et al., Pure Insulin
401 Highly Respirable Powders for Inhalation, Eur J Pharm Sci. (2013).
402 doi:10.1016/j.ejps.2013.08.009.
- 403 [17] R. Vehring, Pharmaceutical particle engineering via spray drying, Pharm Res. 25 (2008) 999–
404 1022. doi:10.1007/s11095-007-9475-1.
- 405 [18] S.R. Gopireddy, E. Gutheil, Numerical simulation of evaporation and drying of a bi-
406 component droplet, International Journal of Heat and Mass Transfer 66 (2013), 404–411.
407 doi:10.1016/j.ijheatmasstransfer.2013.07.010.
- 408 [19] F. Wan, A. Bohr, M.J. Maltesen, S. Bjerregaard, C. Foged, J. Rantanen, et al., Critical solvent
409 properties affecting the particle formation process and characteristics of celecoxib-loaded plga
410 microparticles via spray-drying, Pharm Res. 30 (2013) 1065–1076. doi:10.1007/s11095-012-
411 0943-x.
- 412 [20] S. Belotti, A. Rossi, P. Colombo, R. Bettini, D. Rekkas, S. Politis, et al., Spray-dried
413 Amikacin Powder for Inhalation in Cystic Fibrosis Patients: A Quality by Design Approach
414 for Product Construction, Int J Pharm. (2014). doi:10.1016/j.ijpharm.2014.05.055.
- 415 [21] E.E. Hills, M.H. Abraham, A. Hersey, C.D. Bevan, Diffusion coefficients in ethanol and in
416 water at 298K: Linear free energy relationships, Fluid Phase Equilibria. (2011).
- 417 [22] M.E. Young, P.A. Carroad, R.L. Bell, Estimation of diffusion coefficients of proteins,
418 Biotechnology and Bioengineering 22 (1980), 947-955 DOI: 10.1002/bit.260220504.

Figure Legends

419

420

421 Figure 1. Contour plot of water content as function of feed solution rate and ethanol
422 proportion at the drying temperature of 165 °C (red: high water content; blue low water
423 content).

424

425 Figure 2. SEM pictures of three spray-dried powders at two magnifications (in brackets
426 combinations of factor levels are presented): powder #14 (0% EtOH – 3.5 ml/min – 165 °C);
427 powder #15 (5% EtOH – 3.5 ml/min – 165 °C) and powder #13 (10% EtOH – 3.5 ml/min –
428 165 °C).

429

430 Figure 3. Bulk density of the spray-dried powders. In the square, the amikacin powders made
431 in absence of ethanol.

432

433 Figure 4. Optical microscope pictures of agglomerated powders: batch #14 and batch #15 bis.

434

435 Figure 5. Emitted Dose (left) and Fine Particle Dose (right) values of spray-dried powders
436 (open circle: before agglomeration; black circle: after agglomeration).

437

438 Figure 6. Perturbation plots for Emitted Dose (ED) and Fine Particle Dose (FPD). A: drying
439 temperature; B: feed rate; C: Ethanol proportion.

440

441 Figure 7. 3D plots for Emitted Dose (left) and Fine Particle Dose (right) as a function of feed
442 rate and ethanol proportion at the medium level of drying temperature (165 °C).

Tables

Table 1. Matrix of the face centered-CCD showing the studied parameters, their levels and the experiment number (#) including the replicated center points (#15).

Exp.	A. Drying Temp	B. Feed Rate	C. Ethanol
#	(°C)	(ml/min)	(%w/w)
1	150	2.0	10
2	180	2.0	10
3	150	5.0	10
4	180	5.0	10
5	150	2.0	0
6	180	2.0	0
7	150	5.0	0
8	180	5.0	0
9	150	3.5	5
10	180	3.5	5
11	165	2.0	5
12	165	5.0	5
13	165	3.5	10
14	165	3.5	0
15	165	3.5	5
15 bis	165	3.5	5
15 ter	165	3.5	5

Table 2. Residual water content and particle size distribution (volume diameter and span) of amikacin spray dried powders (n=3).

#	Residual water		Volume Diameter (μm)		
	(%)	$D_{(v,10)}$	$D_{(v,50)}$	$D_{(v,90)}$	Span
1	6.98 ± 0.35	1.23 ± 0.07	2.80 ± 0.25	7.41 ± 0.58	2.19 ± 0.04
2	7.99 ± 0.41	1.19 ± 0.03	2.72 ± 0.08	7.21 ± 0.25	2.22 ± 0.02
3	9.02 ± 0.27	1.32 ± 0.06	3.23 ± 0.33	8.71 ± 0.83	2.29 ± 0.01
4	7.70 ± 0.42	1.39 ± 0.02	3.25 ± 0.12	8.64 ± 0.68	2.40 ± 0.09
5	6.53 ± 0.51	1.45 ± 0.01	2.53 ± 0.07	4.48 ± 0.39	1.20 ± 0.12
6	4.92 ± 0.28	1.35 ± 0.01	2.37 ± 0.01	4.08 ± 0.03	1.16 ± 0.01
7	7.45 ± 0.41	1.44 ± 0.07	2.32 ± 0.09	4.69 ± 0.32	1.40 ± 0.08
8	6.57 ± 0.51	1.36 ± 0.04	2.49 ± 0.07	4.52 ± 0.05	1.29 ± 0.04
9	8.19 ± 0.23	1.41 ± 0.03	2.60 ± 0.04	4.71 ± 0.00	1.27 ± 0.03
10	8.29 ± 0.40	1.29 ± 0.01	3.21 ± 0.12	8.88 ± 0.42	2.37 ± 0.04
11	7.70 ± 0.19	1.21 ± 0.02	2.64 ± 0.09	6.89 ± 0.37	2.19 ± 0.06
12	8.84 ± 0.39	1.40 ± 0.04	3.68 ± 0.13	9.68 ± 0.22	2.25 ± 0.03
13	8.81 ± 0.35	1.18 ± 0.10	2.73 ± 0.12	8.30 ± 0.08	2.37 ± 0.08
14	5.50 ± 0.10	1.44 ± 0.01	2.60 ± 0.08	4.59 ± 0.18	1.21 ± 0.03
15	8.30 ± 0.11	1.32 ± 0.02	3.33 ± 0.07	8.29 ± 0.30	2.26 ± 0.00
15 bis	8.07 ± 0.22	1.36 ± 0.01	3.22 ± 0.11	8.26 ± 0.79	2.14 ± 0.18
15 ter	7.60 ± 0.06	1.37 ± 0.03	3.54 ± 0.01	9.54 ± 0.20	2.31 ± 0.04

Table 3. Aerodynamic assessment of the spray dried powders. Emitted Dose (ED) and Fine Particle Dose (FPD), (n=3)

#	Before agglomeration		After agglomeration	
	ED (mg)	FPD <5 μ m (mg)	ED (mg)	FPD <5 μ m (mg)
1	8.80 \pm 0.20	5.54 \pm 0.59	8.47 \pm 0.93	5.30 \pm 1.00
2	8.60 \pm 0.30	5.59 \pm 0.17	7.53 \pm 1.04	4.48 \pm 0.91
3	8.93 \pm 0.23	5.02 \pm 0.88	7.83 \pm 0.67	5.09 \pm 0.92
4	8.77 \pm 0.25	5.41 \pm 0.46	9.27 \pm 0.81	5.28 \pm 0.42
5	7.27 \pm 0.76	4.70 \pm 0.44	6.77 \pm 0.55	3.72 \pm 0.14
6	7.77 \pm 0.47	5.65 \pm 0.21	7.70 \pm 1.00	3.70 \pm 1.10
7	7.00 \pm 0.69	3.45 \pm 1.14	8.43 \pm 1.40	4.24 \pm 0.17
8	7.23 \pm 0.51	3.87 \pm 0.79	7.53 \pm 0.49	3.94 \pm 0.80
9	8.63 \pm 0.23	4.67 \pm 0.83	7.93 \pm 0.67	3.39 \pm 0.27
10	8.93 \pm 0.46	5.47 \pm 0.53	8.17 \pm 0.23	3.56 \pm 0.34
11	8.10 \pm 0.85	4.19 \pm 0.20	7.87 \pm 0.92	3.64 \pm 0.43
12	8.83 \pm 0.98	4.84 \pm 0.79	8.53 \pm 0.64	3.71 \pm 0.50
13	7.80 \pm 0.30	5.30 \pm 0.39	7.87 \pm 0.06	5.18 \pm 0.51
14	7.87 \pm 0.38	4.81 \pm 0.48	6.80 \pm 0.10	2.86 \pm 0.35
15	8.47 \pm 0.63	4.72 \pm 0.62	8.67 \pm 0.45	4.10 \pm 0.65
15 bis	8.97 \pm 0.60	4.98 \pm 0.53	8.50 \pm 0.17	3.97 \pm 0.14
15 ter	8.43 \pm 0.55	4.58 \pm 0.53	9.10 \pm 0.52	4.63 \pm 0.47

Table 4. Ethanol:water ratio, mean slope of the TGA straight lines, evaporation rate constants (k), Peclet numbers and solubility of amikacin sulphate in the feed solution solvents

EtOH: Water	Slope (s⁻¹)	k (cm²/s)	Peclet Number	Amikacin Sulphate solubility (mg/ml)
0 : 100	1.27 10 ⁻³	3.30 10 ⁻⁴	3.17	309 ± 2
5 : 95	1.28 10 ⁻³	3.33 10 ⁻⁴	3.20	298 ± 3
10 : 90	1.32 10 ⁻³	3.43 10 ⁻⁴	3.29	104 ± 3
100 : 0	-	-	-	3.6 10 ⁻³ ± 0.4 10 ⁻³

Figure1
[Click here to download high resolution image](#)




Figure 2
[Click here to download high resolution image](#)









Figure 3
[Click here to download high resolution image](#)




Figure 4a
[Click here to download high resolution image](#)




Figure 4b
[Click here to download high resolution image](#)



Figure 5a
[Click here to download high resolution image](#)




Figure 5b
[Click here to download high resolution image](#)




Figure 6
[Click here to download high resolution image](#)





Figure 7a
[Click here to download high resolution image](#)




Figure 7b
[Click here to download high resolution image](#)

